Market closed

Silverback Therapeutics/$SPRY

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Silverback Therapeutics

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

Ticker

$SPRY
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
San Diego, United States

Employees

26
Website
ars-pharma.com

SPRY Metrics

BasicAdvanced
$1.1B
-
-$0.51
1.00
-

$1.1B

1

$16.89

$5.75

1.2M

12.56

12.396

0.051

-16.22%

-22.41%

423.659

5.44

5.65

-23.635

8,460.00%

-27.26%

What the Analysts think about SPRY

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Silverback Therapeutics stock.

SPRY Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

SPRY Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

SPRY News

AllArticlesVideos
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.

BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.

Investors Business Daily·1 day ago
ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S

ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S

GlobeNewsWire·1 week ago
ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SPRY

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Silverback Therapeutics stock?

Silverback Therapeutics (SPRY) has a market cap of $1.1B as of January 15, 2025.

What is the P/E ratio for Silverback Therapeutics stock?

The price to earnings (P/E) ratio for Silverback Therapeutics (SPRY) stock is 0 as of January 15, 2025.

Does Silverback Therapeutics stock pay dividends?

No, Silverback Therapeutics (SPRY) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Silverback Therapeutics dividend payment date?

Silverback Therapeutics (SPRY) stock does not pay dividends to its shareholders.

What is the beta indicator for Silverback Therapeutics?

Silverback Therapeutics (SPRY) has a beta rating of 1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.